Medical Affairs, Nutricia Ltd., Trowbridge, UK.
Department of Paediatrics, St. Mary's Hospital, London, UK.
Immun Inflamm Dis. 2022 Mar;10(3):e572. doi: 10.1002/iid3.572. Epub 2021 Dec 6.
Cow's milk allergy (CMA) is common in infants and children. Clinical presentations may vary, with a range of symptoms affecting the gastrointestinal (GI), skin and respiratory systems. Whilst the primary focus of research to date has been on the management of these symptoms, studies investigating the broader clinical burden of CMA are limited.
We performed a retrospective matched cohort study examining clinical data, including allergic symptoms and infections, extracted from case records within The Health Improvement Network database. A total of 6998 children (54% male) were included in the study, including 3499 with CMA (mean age at diagnosis 4.04 months) and 3499 matched controls without CMA, observed for a mean period of 4.2 years.
GI, skin and respiratory symptoms affected significantly more children with CMA (p < .001), which recurred more often (p < .001), compared with children without CMA. More children with CMA had symptoms affecting multiple systems (p < .001). CMA was associated with a greater probability of these symptoms requiring hypoallergenic formula (HAF) prescription persisting over time (log-rank test p < .0001, unadjusted hazard ratio [HR]: 0.81, 95% confidence interval [CI]: 0.76-0.85, p < .001), with a longer median duration of symptoms and HAF prescription compared with the duration of symptoms in those without CMA (3.48 vs. 2.96 years). GI, skin, respiratory and ear infections affected significantly more children with CMA than those without, increasing by 74% (p < .001), 20% (p < .001), 9% (p < .001), and 30% (p < .001) respectively. These infections also recurred more often among children with CMA, increasing by 62% for GI infections, 37% for skin and respiratory infections, and 44% for ear infections (p < .001).
This real-world study provides evidence to suggest that CMA presents a significant clinical burden to children, which has implications for the healthcare system. Further research is warranted to understand the health economic impact of this, and the phenotypes, factors and management approaches which may affect clinical outcomes.
牛奶过敏(CMA)在婴儿和儿童中很常见。临床表现可能多种多样,涉及胃肠道(GI)、皮肤和呼吸系统的一系列症状。虽然迄今为止研究的主要重点是这些症状的管理,但研究 CMA 更广泛的临床负担的研究有限。
我们进行了一项回顾性匹配队列研究,检查了从 The Health Improvement Network 数据库中的病例记录中提取的临床数据,包括过敏症状和感染。共有 6998 名儿童(54%为男性)纳入研究,包括 3499 名 CMA 儿童(平均诊断年龄为 4.04 个月)和 3499 名无 CMA 匹配对照儿童,平均观察 4.2 年。
GI、皮肤和呼吸系统症状影响 CMA 儿童的比例明显更高(p<0.001),且更频繁(p<0.001),与无 CMA 儿童相比。更多的 CMA 儿童有影响多个系统的症状(p<0.001)。CMA 与这些症状需要低敏配方(HAF)处方的可能性增加有关,且随着时间的推移持续存在(对数秩检验 p<0.0001,未调整的危险比[HR]:0.81,95%置信区间[CI]:0.76-0.85,p<0.001),与无 CMA 儿童相比,症状和 HAF 处方的中位持续时间更长(3.48 年 vs. 2.96 年)。GI、皮肤、呼吸和耳部感染影响 CMA 儿童的比例明显高于无 CMA 儿童,分别增加 74%(p<0.001)、20%(p<0.001)、9%(p<0.001)和 30%(p<0.001)。这些感染在 CMA 儿童中也更频繁地复发,GI 感染增加 62%,皮肤和呼吸道感染增加 37%,耳部感染增加 44%(p<0.001)。
这项真实世界研究提供的证据表明,CMA 对儿童的临床负担很大,这对医疗保健系统有影响。需要进一步研究以了解其对健康经济的影响,以及可能影响临床结果的表型、因素和管理方法。